BEGIN:VCALENDAR
VERSION:2.0
CALSCALE:GREGORIAN
PRODID:iCalendar-Ruby
BEGIN:VEVENT
LAST-MODIFIED:20070326T095312
SEQUENCE:0
ORGANIZER:C5
DTEND:20070330T173000
UID:2008-08-22T00:02:33-0400_380061474@socialweb1
DESCRIPTION:_The Latest Innovations and Successful Strategies for Deal Maki
 ng in a Competitive European Market_
\n
\nIn this challenging environment\,
  emerging biotech companies are exploring strategic partnering opportunitie
 s that enhance enterprise value and facilitate management of the significan
 t cost and resource requirements needed to bring a drug to the market. Mean
 while pharmaceutical companies are facing thinning product pipelines and a 
 number of drugs coming off patent\, threatening future revenue streams.
\n

 \nAs a result\, the life sciences sector’s appetite for external deals ha
 s experienced tremendous growth over the last few years as companies take a
 dvantage of M&A and strategic alliances as a pathway for financial success.
 
\n
\nIn the last few months takeovers such as Barr/Pliva\, Merck/Serono\, 
 Nycomed/Altana\, UCB/Schwarz Pharma have shaken up the industry and this co
 nsolidation is building momentum at breakneck speed.
\n
\nIt is therefore v
 ital to have an in-depth and up to the minute understanding of the latest d
 evelopments\, changes in the global marketplace and the hottest techniques 
 and strategies in order to select the right collaborative strategy or fundi
 ng option\, effectively structure the documents\, establish a robust due di
 ligence process and ultimately achieve the best deal. 
\n
\nOur distinguish
 ed faculty will provide you with practical information and insights from th
 eir own experiences on:
\n> How to select the right partner and deal struct
 ure to build a win/win collaboration 
\n> The strategies and pitfalls in ne
 gotiating the key documents 
\n> How to value the deal and negotiate and se
 cure the best price 
\n> Avoiding competition law pitfalls 
\n> What mix of
  funding options should you be considering? 
\n> Key strategies for effecti
 vely structuring the deal 
\n> Due diligence - Tips for finding the warts 

 \n> The private and public M&A process - what works\, how and why 
\n> Fina
 ncing strategy: IPO vs mezzanine vs another private round? 
\n> What is the
  right time for biotech to partner and what are the main assets that pharma
  is looking for? 
\n
SUMMARY:Life Sciences M and A and Strategic Alliances 
DTSTART:20070329T083000
CREATED:20070326T094731
DTSTAMP:20080822T000233
END:VEVENT
END:VCALENDAR